SlideShare ist ein Scribd-Unternehmen logo
1 von 56
Downloaden Sie, um offline zu lesen
Latest	
  Research	
  on	
  Impact	
  of	
  Rx	
  
Drug	
  Abuse	
  on	
  Workers	
  
Compensa:on	
  
Joseph	
  Paduda,	
  President	
  
CompPharma,	
  LLC	
  
Dr.	
  Richard	
  A.	
  Victor,	
  Execu:ve	
  Director	
  
Workers’	
  Compensa:on	
  Research	
  Ins:tute	
  
Disclosures	
  
•  Joseph	
  Paduda	
  has	
  financial	
  rela:onships	
  with	
  
proprietary	
  en::es	
  that	
  produce	
  health	
  care	
  
products	
  and	
  services.	
  	
  These	
  financial	
  
rela:onships	
  are:	
  consul:ng	
  for	
  CID,	
  
Millennium	
  Labs,	
  and	
  MedRisk,	
  Inc.	
  
•  Richard	
  A.	
  Victor	
  has	
  disclosed	
  no	
  relevant,	
  
real	
  or	
  apparent	
  personal	
  or	
  professional	
  
financial	
  rela:onships.	
  
Learning	
  Objec:ves:	
  
1.  Specify	
  workers'	
  comp	
  stakeholders'	
  current	
  aQtudes	
  
towards	
  opioids,	
  the	
  programs	
  they	
  have	
  in	
  place	
  to	
  
address	
  opioids,	
  and	
  how	
  they	
  are	
  measuring	
  success.	
  
2.  Explain	
  the	
  impact	
  of	
  prescrip:on	
  drugs	
  on	
  workers'	
  
compensa:on	
  costs,	
  disability,	
  and	
  outcomes.	
  
3.  Compare	
  the	
  level	
  of	
  understanding	
  of	
  execu:ves	
  to	
  front-­‐
line	
  staff	
  to	
  assess	
  gaps	
  in	
  performance	
  and	
  policy	
  
implementa:on.	
  
4.  Specify	
  what	
  types	
  of	
  physician	
  dispensing	
  of	
  opioids	
  exist	
  
and	
  how	
  common	
  these	
  prac:ces	
  are	
  used.	
  
5.  Analyze	
  whether	
  a	
  ban	
  on	
  physician	
  dispensing	
  of	
  opioids	
  
reduces	
  the	
  use	
  of	
  opioids	
  or	
  merely	
  shiYs	
  the	
  dispensing	
  
to	
  pharmacies.	
  
Latest	
  Research	
  on	
  Impact	
  of	
  Rx	
  
Drug	
  Abuse	
  on	
  Workers	
  
Compensa:on	
  
Joseph	
  Paduda	
  
President	
  
CompPharma,	
  LLC	
  
Opioids are
the most
significant
problem
facing work
comp today.
As a society we consume
of all the opioids prescribed
in the world.
80%
pg.	
  2	
  	
  
DEA definition
“opioid”Examples include the illicit drug heroin and
pharmaceutical drugs like:
OxyContin®
Vicodin®
codeine
morphine
methadone
and
fentanyl
pg.	
  3	
  
Routine use of opioids
for the treatment of
chronic nonmalignant
pain conditions
is not recommended.”
“
-ACOEM
pg.	
  4	
  
The number of narcotics
prescriptions per claim
has grown 41%, from
0.56 in 2003 to 0.79 in 2011.
-NCCI
pg.	
  5	
  	
  
Respondents
400 total, 2:1 front line:
executive ratio
272 completed the survey
Response rate is three times
greater than any other
survey we’ve conducted
over 10 years.
pg.	
  6	
  
Defining the Problem
pg.	
  7	
  
When you hear the word
“opioids,” what one or two
words instantly come to mind? Addiction /
Dependence
Drug(s) /
Narcotics /
Drug Name
Abuse
Appropriate /
Pain / Pain Killer /
Therapy
Cost
Over Prescribed /
Death / Danger /
Epidemic
Death
pg.	
  8	
  
How concerned is
senior management
about opioids
in workers’
compensation?
pg.	
  9	
  	
  
Why? Because these drugs drive up
costs, duration – most respondents have
figured this out and are starting to track
the impact.
pg.	
  10	
  
Opioids are perceived
as having
overwhelmingly
negative
consequences for
payers and claimants.
What is the impact of opioids on the
costs and outcomes of workers’
compensation claims?
pg.	
  11	
  
Whose responsibility is
it to manage opioids?
Addicts may be
“responsible” but
aren’t capable, and
many doctors
aren’t able to
address the issue.
pg.	
  12	
  	
  
How effective or ineffective
have PAYERS been in
addressing opioids?
pg.	
  13	
  	
  
What is causing PAYERS
not to effectively address
the issue of opioids?
Regulations Don’t Allow
Payers to Do Enough
Tools Available
Are Inadequate
Not Able to Identify Claims That
Would Benefit From Intervention
Other (Please Specify)
Not a Top Priority pg.	
  14	
  
How effective have
REGULATORS been in
addressing opioids?
pg.	
  15	
  	
  
Conclusion
major problem as it directly affects
claim costs
duration
risk
ability to control same
As with any WC issue, payers look
to regulators to enable solutions –
however there are some solutions
currently in place that are delivering
results despite the less than
helpful environment.
pg.	
  16	
  	
  
Solutions
pg.	
  17	
  	
  
We’re in the early stages of
figuring out the problem and
developing effective approaches.
pg.	
  18	
  
What is the goal for the stated opioid
program(s)?
What is the goal for the
stated opioid program(s)?
pg.	
  19	
  	
  
What vendor(s) are you working
with to address opioids?
pg.	
  20	
  	
  
Please describe what
the vendor(s) is(are)
doing to address
opioids?
There’s a discrepancy
between front-line staff
and management, which
indicates a disconnect with
internal communication.
pg.	
  21	
  	
  
What is the vendor doing to address opioids?
pg.	
  22	
  	
  
How are you measuring the impact
of the work of the vendor(s)?
pg.	
  23	
  
We’re in this early stage
where much of what we’re
doing is based on what we
think will work, but we
don’t yet KNOW.
Do you believe the programs
are having a positive effect?
pg.	
  24	
  
What should be done?
What is being done?
80% of respondents picked best practices.
vs.
pg.	
  25	
  	
  
The ideal solution
80% identified:
Peer / physician review for claims – 90 / 180 days
Drug utilization review
Random drug testing
Opioid agreement / contracts
pg.	
  26	
  	
  
Please rank the following potential solutions
1-8 in the order that you believe would be
most successful in addressing the overall
opioid issue starting with 1 as most successful.
pg.	
  27	
  	
  
What percentage of the claims with opioid
issues do you think an opioid management
program would address?
pg.	
  28	
  	
  
Takeaways
pg.	
  29	
  	
  
Consensus
that opioids:
Cause addiction /
dependency
Increase disability
duration
Increase risk of
fraud / abuse
Drive up costs
pg.	
  30	
  	
  
Opioid
management
is in its
infancy.
pg.	
  31	
  	
  
There is
a wide
divergence
between ideal
and actual
opioid
management
programs.
pg.	
  32	
  	
  
Treating
physicians
are the crux.
pg.	
  33	
  	
  
Conclusion
pg.	
  34	
  	
  
pg.	
  35	
  	
  
Impact	
  Of	
  Banning	
  Physician	
  Dispensing	
  Of	
  
Stronger	
  Opioids	
  In	
  Florida	
  
Workers	
  Compensa:on	
  Research	
  Ins:tute	
  
April	
  23,	
  2014	
  	
  
© Copyright 2014 WCRI. All Rights Reserved.
•  Two public policy debates converged
– Public health: “Pill mills” that dispense
controlled substances
– Cost: Physician dispensing of a wide range of
Rx in workers’ compensation
•  Florida legislature banned physician
dispensing of stronger opioids
Policy	
  Context	
  In	
  Florida	
  
41© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 41
•  High levels of physician compliance with the ban
•  Fewer Florida workers received stronger opioids
•  Physician-dispensers switched to dispensing
other pain medications rather than continuing
stronger opioids
Major	
  Findings	
  
42© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 42
Source: Impact of Banning Physician Dispensing of Opioids in Florida (Thumula, 2013)
Physician	
  Dispensing	
  Was	
  Common	
  In	
  
Florida,	
  Higher	
  Than	
  Most	
  States	
  
0%
10%
20%
30%
40%
50%
60%
MA
NY
TX
AR
M
NLA
VA
NC
WI
KS
IA
SC
NJ
TN
MO
PA
MI
IN
GA
CT
M
DIL
FL
CA
43
Prescriptions For 2011/12 Claims With > 7 Days Of Lost Time
Source: The Prevalence And Costs Of Physician-Dispensed Drugs (Wang, Liu, & Thumula 2013)
%	
  Of	
  All	
  Rx	
  For	
  Physician-­‐Dispensed	
  Rx	
  
© Copyright 2014 WCRI. All Rights Reserved. 43
Prescriptions For 2011/12 Claims With > 7 Days Of Lost Time
Source: The Prevalence And Costs Of Physician-Dispensed Drugs (Wang, Liu, & Thumula, 2013)
•  Ban on physician dispensing of schedule II, III
controlled substances (effective July 1, 2011)
– Few exceptions (can dispense samples, after
surgeries, clinical trials, department of corrections)
– No limits on physician dispensing of other
medications
•  Requires counterfeit-proof prescription pads
(effective August 29, 2011)
•  Register as controlled substance prescribing
physicians (effective January 1, 2012)
HB	
  7095	
  (Florida	
  Pill	
  Mill	
  Bill)	
  
44© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 44
•  Early impact of reform on prescribing and
dispensing practices
•  Only injuries that occurred after the law
change were included in treatment group
Scope	
  Of	
  The	
  Study	
  
45© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 45
•  Pre-post policy implementation
–  Treatment group: new injuries arising between
July-September, 2011 (Ban effective 7/1/11)
–  Comparison group: new injuries arising between
July-September, 2010
–  Both groups had Rx filled through December of the year
of injury (3-6 months of experience)
•  Data:
–  25% of Florida claims
–  Indemnity and medical-only claims
–  Case-mix adjusted
Methods	
  And	
  Data	
  
46© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 46
Pre-­‐	
  And	
  Post-­‐Reform	
  Claim	
  
Characteris:cs	
  Were	
  Similar	
  
47© Copyright 2014 WCRI. All Rights Reserved.
Pre-­‐Reform	
   Post-­‐Reform	
  
Number	
  Of	
  Claims	
   11,867	
   10,623	
  
Average	
  Age	
   41	
   41	
  
%	
  Female	
   42%	
   40%	
  
%	
  Indemnity	
  Claims	
   24%	
   22%	
  
Average	
  Medical	
  Payments	
   $2,464	
   $2,521	
  
Average	
  #	
  Physician	
  Visits	
   3	
   3	
  
© Copyright 2014 WCRI. All Rights Reserved. 47
Source: Impact of Banning Physician Dispensing of Opioids in Florida (Thumula, 2013)
Physician	
  Dispensing	
  And	
  Use	
  Of	
  Pain	
  
Medica:ons	
  Unchanged	
  
48© Copyright 2014 WCRI. All Rights Reserved.
Pre-­‐Reform	
   Post-­‐Reform	
  
Number	
  of	
  Rxs	
   22,255	
   19,017	
  
%	
  Physician-­‐Dispensed	
  Rxs	
   52%	
   52%	
  
%	
  All	
  Pain	
  Medica:ons	
   61%	
   61%	
  
© Copyright 2014 WCRI. All Rights Reserved. 48
High	
  Physician	
  Compliance	
  With	
  Reform	
  
In	
  First	
  3-­‐6	
  Months	
  Of	
  Cases	
  
49© Copyright 2014 WCRI. All Rights Reserved.
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
4.0%
Pre-Reform Post-Reform
ProportionOfClaimsWithRx
Physician-­‐Dispensed	
  Schedule	
  II,	
  III	
  Opioids	
  
© Copyright 2014 WCRI. All Rights Reserved. 49
•  Of those with physician-dispensed stronger
opioids after the ban:
– 69% surgical cases
– 21% out-of-state providers
Why	
  Didn’t	
  Physician-­‐Dispensed	
  	
  
Schedule	
  II,	
  III	
  Opioids	
  Drop	
  To	
  Zero?	
  
50© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 50
Physician	
  Dispensing	
  Of	
  Stronger	
  Opioids	
  
Fell	
  AYer	
  The	
  Ban	
  
3.5%
0.5%
Pre-Reform Post-Reform
ProportionOfClaimsWithRx
51© Copyright 2014 WCRI. All Rights Reserved.
Physician-­‐
Dispensed	
  
Opioids	
  (II,	
  III)	
  
© Copyright 2014 WCRI. All Rights Reserved. 51
No	
  Change	
  In	
  Pharmacy	
  Dispensing	
  Of	
  
Schedule	
  II,	
  III	
  Opioids	
  
12.0% 12.1%
3.5%
0.5%
Pre-Reform Post-Reform
ProportionOfClaimsWithRx
52© Copyright 2014 WCRI. All Rights Reserved.
Physician-­‐
Dispensed	
  
Opioids	
  (II,	
  III)	
  
Pharmacy-­‐
Dispensed	
  
Opioids	
  (II,	
  III)	
  
© Copyright 2014 WCRI. All Rights Reserved. 52
Physician	
  Dispensing	
  Of	
  NSAIDs	
  And	
  Weaker	
  
Opioids	
  Increased	
  Post-­‐Reform	
  
9.0% 9.8%
23.8% 26.0%
3.5%
0.5%
Pre-Reform Post-Reform
ProportionOfClaimsWithRx
53© Copyright 2014 WCRI. All Rights Reserved.
Physician-­‐
Dispensed	
  
Opioids	
  (II,	
  III)	
  
Physician-­‐
Dispensed	
  
Weaker	
  Opioids	
  
Physician-­‐
Dispensed	
  NSAIDs	
  
© Copyright 2014 WCRI. All Rights Reserved. 53
Recap:	
  Did	
  The	
  Florida	
  Ban	
  Reduce	
  The	
  Overall	
  
Use	
  Of	
  Opioids	
  By	
  Injured	
  Workers?	
  	
  
•  High levels of physician compliance with the ban
•  Fewer workers received stronger opioids
54© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 54
Ques:on	
  Raised:	
  	
  Does	
  Physician	
  
Dispensing	
  Lead	
  To	
  More	
  Opioids?	
  
•  Physician-­‐dispensers	
  switched	
  to	
  other	
  pain	
  
medica:ons	
  in	
  the	
  wake	
  of	
  the	
  ban	
  
— No	
  change	
  in	
  pharmacy-­‐dispensed	
  schedule	
  II,	
  III	
  
opioids	
  
— Increase	
  in	
  percentage	
  of	
  claims	
  with	
  physician-­‐
dispensed	
  NSAIDs	
  and	
  weaker	
  opioids	
  
•  This	
  raises	
  ques:ons	
  if	
  physicians	
  dispensed	
  
unnecessary	
  opioids	
  pre-­‐ban	
  	
  
•  Upcoming	
  study	
  will	
  examine	
  longer-­‐term	
  
impact	
  of	
  the	
  ban	
  
55© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 55
•  To purchase the study, Impact of Banning
Physician Dispensing of Opioids in Florida, go
to:
•  WWW.WCRINET.ORG
•  For comments/questions about the findings:
WCRI@WCRINET.ORG
Follow WCRI on social media:
For	
  More	
  Informa:on	
  
56© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 56

Weitere ähnliche Inhalte

Was ist angesagt?

Goal 1 improve the accuracy of patient identification.nps
Goal 1 improve the accuracy of patient identification.npsGoal 1 improve the accuracy of patient identification.nps
Goal 1 improve the accuracy of patient identification.npsssuser47f0be
 
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar SlidesPan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar SlidesCanadian Organization for Rare Disorders
 
The ROI of Avoiding Antibiotic Overuse
The ROI of Avoiding Antibiotic OveruseThe ROI of Avoiding Antibiotic Overuse
The ROI of Avoiding Antibiotic OverusePYA, P.C.
 
WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...
WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...
WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...Nathan White, CPC
 
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...Nathan White, CPC
 
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinalCadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinalCADTH Symposium
 
Findings from a 5-yr Research Project on Pathways to Treatment for Substance ...
Findings from a 5-yr Research Project on Pathways to Treatment for Substance ...Findings from a 5-yr Research Project on Pathways to Treatment for Substance ...
Findings from a 5-yr Research Project on Pathways to Treatment for Substance ...Bernie McCann
 
How much does it cost to launch and commercialize a companion diagnostic test?
How much does it cost to launch and commercialize a companion diagnostic test?How much does it cost to launch and commercialize a companion diagnostic test?
How much does it cost to launch and commercialize a companion diagnostic test?Diaceutics Group
 
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices
 
The Powerful and Evolving Role of Patient Advocacy Groups in Orphan Drug Deve...
The Powerful and Evolving Role ofPatient Advocacy Groups in Orphan Drug Deve...The Powerful and Evolving Role ofPatient Advocacy Groups in Orphan Drug Deve...
The Powerful and Evolving Role of Patient Advocacy Groups in Orphan Drug Deve...PremierResearch_
 
Drug & Device Liability Forum
Drug & Device Liability ForumDrug & Device Liability Forum
Drug & Device Liability ForumJoel Keitner
 
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...Arvind Mani
 
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...Big Data: Implications of Data Mining for Employed Physician Compliance Manag...
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...PYA, P.C.
 
Deloitte innovacion health
Deloitte innovacion healthDeloitte innovacion health
Deloitte innovacion healthgbra80
 
Comparative Effectiveness Research CER: A New Current In Pharmaceutical Bran...
Comparative Effectiveness Research CER:  A New Current In Pharmaceutical Bran...Comparative Effectiveness Research CER:  A New Current In Pharmaceutical Bran...
Comparative Effectiveness Research CER: A New Current In Pharmaceutical Bran...JGB1
 
Fulgent Genetics - Biotech - Total return >200%
Fulgent Genetics - Biotech - Total return >200%Fulgent Genetics - Biotech - Total return >200%
Fulgent Genetics - Biotech - Total return >200%Rogelio Rea
 
Reimbursement Strategy for Companion Diagnostics
Reimbursement Strategy for Companion DiagnosticsReimbursement Strategy for Companion Diagnostics
Reimbursement Strategy for Companion DiagnosticsEdward Berger
 
The State of Clinical Outsourcing
The State of Clinical OutsourcingThe State of Clinical Outsourcing
The State of Clinical OutsourcingThe Avoca Group
 

Was ist angesagt? (19)

Goal 1 improve the accuracy of patient identification.nps
Goal 1 improve the accuracy of patient identification.npsGoal 1 improve the accuracy of patient identification.nps
Goal 1 improve the accuracy of patient identification.nps
 
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar SlidesPan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
Pan-Canadian Pharmaceutical Alliance – a Primer June 22, 2016 Webinar Slides
 
How Prescription Drugs are Approved in Canada
How Prescription Drugs are Approved in CanadaHow Prescription Drugs are Approved in Canada
How Prescription Drugs are Approved in Canada
 
The ROI of Avoiding Antibiotic Overuse
The ROI of Avoiding Antibiotic OveruseThe ROI of Avoiding Antibiotic Overuse
The ROI of Avoiding Antibiotic Overuse
 
WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...
WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...
WHITE PAPER: What’s Next in US Payor Communications: The Impact of FDA's Prop...
 
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
What’s Next in US Payor Communications: The Impact of FDA's Proposed Guidance...
 
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinalCadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
Cadth 2015 b1 slides allan grill-pcodr-cadth_symposium2015presentationfinal
 
Findings from a 5-yr Research Project on Pathways to Treatment for Substance ...
Findings from a 5-yr Research Project on Pathways to Treatment for Substance ...Findings from a 5-yr Research Project on Pathways to Treatment for Substance ...
Findings from a 5-yr Research Project on Pathways to Treatment for Substance ...
 
How much does it cost to launch and commercialize a companion diagnostic test?
How much does it cost to launch and commercialize a companion diagnostic test?How much does it cost to launch and commercialize a companion diagnostic test?
How much does it cost to launch and commercialize a companion diagnostic test?
 
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...
Best Practices in Patient Advocacy Groups Collaboration and Relationship Mana...
 
The Powerful and Evolving Role of Patient Advocacy Groups in Orphan Drug Deve...
The Powerful and Evolving Role ofPatient Advocacy Groups in Orphan Drug Deve...The Powerful and Evolving Role ofPatient Advocacy Groups in Orphan Drug Deve...
The Powerful and Evolving Role of Patient Advocacy Groups in Orphan Drug Deve...
 
Drug & Device Liability Forum
Drug & Device Liability ForumDrug & Device Liability Forum
Drug & Device Liability Forum
 
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
Market Access Climate Change Webinar_the Evolving Impact of Product Listing A...
 
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...Big Data: Implications of Data Mining for Employed Physician Compliance Manag...
Big Data: Implications of Data Mining for Employed Physician Compliance Manag...
 
Deloitte innovacion health
Deloitte innovacion healthDeloitte innovacion health
Deloitte innovacion health
 
Comparative Effectiveness Research CER: A New Current In Pharmaceutical Bran...
Comparative Effectiveness Research CER:  A New Current In Pharmaceutical Bran...Comparative Effectiveness Research CER:  A New Current In Pharmaceutical Bran...
Comparative Effectiveness Research CER: A New Current In Pharmaceutical Bran...
 
Fulgent Genetics - Biotech - Total return >200%
Fulgent Genetics - Biotech - Total return >200%Fulgent Genetics - Biotech - Total return >200%
Fulgent Genetics - Biotech - Total return >200%
 
Reimbursement Strategy for Companion Diagnostics
Reimbursement Strategy for Companion DiagnosticsReimbursement Strategy for Companion Diagnostics
Reimbursement Strategy for Companion Diagnostics
 
The State of Clinical Outsourcing
The State of Clinical OutsourcingThe State of Clinical Outsourcing
The State of Clinical Outsourcing
 

Ähnlich wie Tpp 5 paduda victor

Rx15 tpp wed_430_1_henderson_2anderson-emptage
Rx15 tpp wed_430_1_henderson_2anderson-emptageRx15 tpp wed_430_1_henderson_2anderson-emptage
Rx15 tpp wed_430_1_henderson_2anderson-emptageOPUNITE
 
Five Questions” You will write responses to five (5.docx
Five Questions” You will write responses to five (5.docxFive Questions” You will write responses to five (5.docx
Five Questions” You will write responses to five (5.docxRAJU852744
 
Drug Discovery, Development and Commercialization
Drug Discovery, Development and CommercializationDrug Discovery, Development and Commercialization
Drug Discovery, Development and CommercializationBashant Kumar sah
 
The FDA and industry: A recipe for collaborating in the New Health Economy
The FDA and industry:  A recipe for collaborating in the New Health EconomyThe FDA and industry:  A recipe for collaborating in the New Health Economy
The FDA and industry: A recipe for collaborating in the New Health EconomyPwC
 
White Paper: Best Practices for Medical Benefit Management (MBM)
White Paper: Best Practices for Medical Benefit Management (MBM)White Paper: Best Practices for Medical Benefit Management (MBM)
White Paper: Best Practices for Medical Benefit Management (MBM)Tai Freligh
 
Cost saving strategies_updated
Cost saving strategies_updatedCost saving strategies_updated
Cost saving strategies_updatedOPUNITE
 
Are You Ready for EPCS? Becoming mandatory before you know it.
Are You Ready for EPCS?  Becoming mandatory before you know it.Are You Ready for EPCS?  Becoming mandatory before you know it.
Are You Ready for EPCS? Becoming mandatory before you know it.David Lovelace, CPHIMS, MHSA
 
E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...
E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...
E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...Forward360 LLC
 
8 pharmacy track pharmacists working with local coalitions and pdm ps
8 pharmacy track pharmacists working with local coalitions and pdm ps8 pharmacy track pharmacists working with local coalitions and pdm ps
8 pharmacy track pharmacists working with local coalitions and pdm psOPUNITE
 
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranRevised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranOPUNITE
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerOPUNITE
 
Global issues 12.5.13
Global issues 12.5.13Global issues 12.5.13
Global issues 12.5.13dbrown2014
 
BioTech Medical Solutions - Pain RD short 8.5x11
BioTech Medical Solutions - Pain RD short 8.5x11BioTech Medical Solutions - Pain RD short 8.5x11
BioTech Medical Solutions - Pain RD short 8.5x11William Tillman
 
Designing clinical trials on lifestyle interventions using patient reported o...
Designing clinical trials on lifestyle interventions using patient reported o...Designing clinical trials on lifestyle interventions using patient reported o...
Designing clinical trials on lifestyle interventions using patient reported o...Jim Roldan
 
Rx15 pdmp wed_430_1_stanton_2blake_3ramsey
Rx15 pdmp wed_430_1_stanton_2blake_3ramseyRx15 pdmp wed_430_1_stanton_2blake_3ramsey
Rx15 pdmp wed_430_1_stanton_2blake_3ramseyOPUNITE
 
xRx15 vision wed_200_surgical_momentum
xRx15 vision wed_200_surgical_momentumxRx15 vision wed_200_surgical_momentum
xRx15 vision wed_200_surgical_momentumOPUNITE
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioOPUNITE
 
PHARMACOVIGILANCE COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated IN 202...
PHARMACOVIGILANCE  COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated IN 202...PHARMACOVIGILANCE  COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated IN 202...
PHARMACOVIGILANCE COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated IN 202...Pristyn Research Solutions
 
Challenges for drug development jsr slides aug 2013
Challenges for drug development jsr slides aug 2013Challenges for drug development jsr slides aug 2013
Challenges for drug development jsr slides aug 2013CincyTechUSA
 

Ähnlich wie Tpp 5 paduda victor (20)

Rx15 tpp wed_430_1_henderson_2anderson-emptage
Rx15 tpp wed_430_1_henderson_2anderson-emptageRx15 tpp wed_430_1_henderson_2anderson-emptage
Rx15 tpp wed_430_1_henderson_2anderson-emptage
 
Five Questions” You will write responses to five (5.docx
Five Questions” You will write responses to five (5.docxFive Questions” You will write responses to five (5.docx
Five Questions” You will write responses to five (5.docx
 
Drug Discovery, Development and Commercialization
Drug Discovery, Development and CommercializationDrug Discovery, Development and Commercialization
Drug Discovery, Development and Commercialization
 
The FDA and industry: A recipe for collaborating in the New Health Economy
The FDA and industry:  A recipe for collaborating in the New Health EconomyThe FDA and industry:  A recipe for collaborating in the New Health Economy
The FDA and industry: A recipe for collaborating in the New Health Economy
 
Hta basic introduction
Hta basic introductionHta basic introduction
Hta basic introduction
 
White Paper: Best Practices for Medical Benefit Management (MBM)
White Paper: Best Practices for Medical Benefit Management (MBM)White Paper: Best Practices for Medical Benefit Management (MBM)
White Paper: Best Practices for Medical Benefit Management (MBM)
 
Cost saving strategies_updated
Cost saving strategies_updatedCost saving strategies_updated
Cost saving strategies_updated
 
Are You Ready for EPCS? Becoming mandatory before you know it.
Are You Ready for EPCS?  Becoming mandatory before you know it.Are You Ready for EPCS?  Becoming mandatory before you know it.
Are You Ready for EPCS? Becoming mandatory before you know it.
 
E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...
E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...
E-Prescribing Controlled Substances: Opportunities and Experiences - May 2014...
 
8 pharmacy track pharmacists working with local coalitions and pdm ps
8 pharmacy track pharmacists working with local coalitions and pdm ps8 pharmacy track pharmacists working with local coalitions and pdm ps
8 pharmacy track pharmacists working with local coalitions and pdm ps
 
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranRevised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebran
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
 
Global issues 12.5.13
Global issues 12.5.13Global issues 12.5.13
Global issues 12.5.13
 
BioTech Medical Solutions - Pain RD short 8.5x11
BioTech Medical Solutions - Pain RD short 8.5x11BioTech Medical Solutions - Pain RD short 8.5x11
BioTech Medical Solutions - Pain RD short 8.5x11
 
Designing clinical trials on lifestyle interventions using patient reported o...
Designing clinical trials on lifestyle interventions using patient reported o...Designing clinical trials on lifestyle interventions using patient reported o...
Designing clinical trials on lifestyle interventions using patient reported o...
 
Rx15 pdmp wed_430_1_stanton_2blake_3ramsey
Rx15 pdmp wed_430_1_stanton_2blake_3ramseyRx15 pdmp wed_430_1_stanton_2blake_3ramsey
Rx15 pdmp wed_430_1_stanton_2blake_3ramsey
 
xRx15 vision wed_200_surgical_momentum
xRx15 vision wed_200_surgical_momentumxRx15 vision wed_200_surgical_momentum
xRx15 vision wed_200_surgical_momentum
 
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioWeb only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachio
 
PHARMACOVIGILANCE COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated IN 202...
PHARMACOVIGILANCE  COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated IN 202...PHARMACOVIGILANCE  COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated IN 202...
PHARMACOVIGILANCE COMMON JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated IN 202...
 
Challenges for drug development jsr slides aug 2013
Challenges for drug development jsr slides aug 2013Challenges for drug development jsr slides aug 2013
Challenges for drug development jsr slides aug 2013
 

Mehr von OPUNITE

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynoteOPUNITE
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynoteOPUNITE
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynoteOPUNITE
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_finalOPUNITE
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingOPUNITE
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyOPUNITE
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliOPUNITE
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesOPUNITE
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessOPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingOPUNITE
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceOPUNITE
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleOPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattOPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerOPUNITE
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_groupOPUNITE
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldOPUNITE
 

Mehr von OPUNITE (20)

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
 

Kürzlich hochgeladen

VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service LucknowVIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknownarwatsonia7
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...narwatsonia7
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingArunagarwal328757
 
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service LucknowCall Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknownarwatsonia7
 
Call Girl Nagpur Sia 7001305949 Independent Escort Service Nagpur
Call Girl Nagpur Sia 7001305949 Independent Escort Service NagpurCall Girl Nagpur Sia 7001305949 Independent Escort Service Nagpur
Call Girl Nagpur Sia 7001305949 Independent Escort Service NagpurRiya Pathan
 
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment BookingCall Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment BookingNehru place Escorts
 
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Availablenarwatsonia7
 
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...narwatsonia7
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original PhotosCall Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photosnarwatsonia7
 
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Availablenarwatsonia7
 
Noida Sector 135 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few C...
Noida Sector 135 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few C...Noida Sector 135 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few C...
Noida Sector 135 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few C...rajnisinghkjn
 
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort ServiceCollege Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort ServiceNehru place Escorts
 
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...narwatsonia7
 
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service JaipurHigh Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipurparulsinha
 
Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024Gabriel Guevara MD
 
Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...
Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...
Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...narwatsonia7
 

Kürzlich hochgeladen (20)

VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service LucknowVIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
VIP Call Girls Lucknow Nandini 7001305949 Independent Escort Service Lucknow
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
Russian Call Girls Chickpet - 7001305949 Booking and charges genuine rate for...
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, Pricing
 
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service LucknowCall Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
Call Girl Lucknow Mallika 7001305949 Independent Escort Service Lucknow
 
Call Girl Nagpur Sia 7001305949 Independent Escort Service Nagpur
Call Girl Nagpur Sia 7001305949 Independent Escort Service NagpurCall Girl Nagpur Sia 7001305949 Independent Escort Service Nagpur
Call Girl Nagpur Sia 7001305949 Independent Escort Service Nagpur
 
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment BookingCall Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
Call Girls Service Nandiambakkam | 7001305949 At Low Cost Cash Payment Booking
 
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Jp Nagar Just Call 7001305949 Top Class Call Girl Service Available
 
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
Call Girls Kanakapura Road Just Call 7001305949 Top Class Call Girl Service A...
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original PhotosCall Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
Call Girl Service Bidadi - For 7001305949 Cheap & Best with original Photos
 
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service AvailableCall Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
Call Girls Hsr Layout Just Call 7001305949 Top Class Call Girl Service Available
 
Noida Sector 135 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few C...
Noida Sector 135 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few C...Noida Sector 135 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few C...
Noida Sector 135 Call Girls ( 9873940964 ) Book Hot And Sexy Girls In A Few C...
 
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort ServiceCollege Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
College Call Girls Vyasarpadi Whatsapp 7001305949 Independent Escort Service
 
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
Call Girls Service in Bommanahalli - 7001305949 with real photos and phone nu...
 
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service JaipurHigh Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
High Profile Call Girls Jaipur Vani 8445551418 Independent Escort Service Jaipur
 
Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024Asthma Review - GINA guidelines summary 2024
Asthma Review - GINA guidelines summary 2024
 
Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...
Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...
Russian Call Girls Gunjur Mugalur Road : 7001305949 High Profile Model Escort...
 

Tpp 5 paduda victor

  • 1. Latest  Research  on  Impact  of  Rx   Drug  Abuse  on  Workers   Compensa:on   Joseph  Paduda,  President   CompPharma,  LLC   Dr.  Richard  A.  Victor,  Execu:ve  Director   Workers’  Compensa:on  Research  Ins:tute  
  • 2. Disclosures   •  Joseph  Paduda  has  financial  rela:onships  with   proprietary  en::es  that  produce  health  care   products  and  services.    These  financial   rela:onships  are:  consul:ng  for  CID,   Millennium  Labs,  and  MedRisk,  Inc.   •  Richard  A.  Victor  has  disclosed  no  relevant,   real  or  apparent  personal  or  professional   financial  rela:onships.  
  • 3. Learning  Objec:ves:   1.  Specify  workers'  comp  stakeholders'  current  aQtudes   towards  opioids,  the  programs  they  have  in  place  to   address  opioids,  and  how  they  are  measuring  success.   2.  Explain  the  impact  of  prescrip:on  drugs  on  workers'   compensa:on  costs,  disability,  and  outcomes.   3.  Compare  the  level  of  understanding  of  execu:ves  to  front-­‐ line  staff  to  assess  gaps  in  performance  and  policy   implementa:on.   4.  Specify  what  types  of  physician  dispensing  of  opioids  exist   and  how  common  these  prac:ces  are  used.   5.  Analyze  whether  a  ban  on  physician  dispensing  of  opioids   reduces  the  use  of  opioids  or  merely  shiYs  the  dispensing   to  pharmacies.  
  • 4. Latest  Research  on  Impact  of  Rx   Drug  Abuse  on  Workers   Compensa:on   Joseph  Paduda   President   CompPharma,  LLC  
  • 6. As a society we consume of all the opioids prescribed in the world. 80% pg.  2    
  • 7. DEA definition “opioid”Examples include the illicit drug heroin and pharmaceutical drugs like: OxyContin® Vicodin® codeine morphine methadone and fentanyl pg.  3  
  • 8. Routine use of opioids for the treatment of chronic nonmalignant pain conditions is not recommended.” “ -ACOEM pg.  4  
  • 9. The number of narcotics prescriptions per claim has grown 41%, from 0.56 in 2003 to 0.79 in 2011. -NCCI pg.  5    
  • 10. Respondents 400 total, 2:1 front line: executive ratio 272 completed the survey Response rate is three times greater than any other survey we’ve conducted over 10 years. pg.  6  
  • 12. When you hear the word “opioids,” what one or two words instantly come to mind? Addiction / Dependence Drug(s) / Narcotics / Drug Name Abuse Appropriate / Pain / Pain Killer / Therapy Cost Over Prescribed / Death / Danger / Epidemic Death pg.  8  
  • 13. How concerned is senior management about opioids in workers’ compensation? pg.  9    
  • 14. Why? Because these drugs drive up costs, duration – most respondents have figured this out and are starting to track the impact. pg.  10  
  • 15. Opioids are perceived as having overwhelmingly negative consequences for payers and claimants. What is the impact of opioids on the costs and outcomes of workers’ compensation claims? pg.  11  
  • 16. Whose responsibility is it to manage opioids? Addicts may be “responsible” but aren’t capable, and many doctors aren’t able to address the issue. pg.  12    
  • 17. How effective or ineffective have PAYERS been in addressing opioids? pg.  13    
  • 18. What is causing PAYERS not to effectively address the issue of opioids? Regulations Don’t Allow Payers to Do Enough Tools Available Are Inadequate Not Able to Identify Claims That Would Benefit From Intervention Other (Please Specify) Not a Top Priority pg.  14  
  • 19. How effective have REGULATORS been in addressing opioids? pg.  15    
  • 20. Conclusion major problem as it directly affects claim costs duration risk ability to control same As with any WC issue, payers look to regulators to enable solutions – however there are some solutions currently in place that are delivering results despite the less than helpful environment. pg.  16    
  • 22. We’re in the early stages of figuring out the problem and developing effective approaches. pg.  18  
  • 23. What is the goal for the stated opioid program(s)? What is the goal for the stated opioid program(s)? pg.  19    
  • 24. What vendor(s) are you working with to address opioids? pg.  20    
  • 25. Please describe what the vendor(s) is(are) doing to address opioids? There’s a discrepancy between front-line staff and management, which indicates a disconnect with internal communication. pg.  21    
  • 26. What is the vendor doing to address opioids? pg.  22    
  • 27. How are you measuring the impact of the work of the vendor(s)? pg.  23  
  • 28. We’re in this early stage where much of what we’re doing is based on what we think will work, but we don’t yet KNOW. Do you believe the programs are having a positive effect? pg.  24  
  • 29. What should be done? What is being done? 80% of respondents picked best practices. vs. pg.  25    
  • 30. The ideal solution 80% identified: Peer / physician review for claims – 90 / 180 days Drug utilization review Random drug testing Opioid agreement / contracts pg.  26    
  • 31. Please rank the following potential solutions 1-8 in the order that you believe would be most successful in addressing the overall opioid issue starting with 1 as most successful. pg.  27    
  • 32. What percentage of the claims with opioid issues do you think an opioid management program would address? pg.  28    
  • 34. Consensus that opioids: Cause addiction / dependency Increase disability duration Increase risk of fraud / abuse Drive up costs pg.  30    
  • 36. There is a wide divergence between ideal and actual opioid management programs. pg.  32    
  • 40. Impact  Of  Banning  Physician  Dispensing  Of   Stronger  Opioids  In  Florida   Workers  Compensa:on  Research  Ins:tute   April  23,  2014     © Copyright 2014 WCRI. All Rights Reserved.
  • 41. •  Two public policy debates converged – Public health: “Pill mills” that dispense controlled substances – Cost: Physician dispensing of a wide range of Rx in workers’ compensation •  Florida legislature banned physician dispensing of stronger opioids Policy  Context  In  Florida   41© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 41
  • 42. •  High levels of physician compliance with the ban •  Fewer Florida workers received stronger opioids •  Physician-dispensers switched to dispensing other pain medications rather than continuing stronger opioids Major  Findings   42© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 42 Source: Impact of Banning Physician Dispensing of Opioids in Florida (Thumula, 2013)
  • 43. Physician  Dispensing  Was  Common  In   Florida,  Higher  Than  Most  States   0% 10% 20% 30% 40% 50% 60% MA NY TX AR M NLA VA NC WI KS IA SC NJ TN MO PA MI IN GA CT M DIL FL CA 43 Prescriptions For 2011/12 Claims With > 7 Days Of Lost Time Source: The Prevalence And Costs Of Physician-Dispensed Drugs (Wang, Liu, & Thumula 2013) %  Of  All  Rx  For  Physician-­‐Dispensed  Rx   © Copyright 2014 WCRI. All Rights Reserved. 43 Prescriptions For 2011/12 Claims With > 7 Days Of Lost Time Source: The Prevalence And Costs Of Physician-Dispensed Drugs (Wang, Liu, & Thumula, 2013)
  • 44. •  Ban on physician dispensing of schedule II, III controlled substances (effective July 1, 2011) – Few exceptions (can dispense samples, after surgeries, clinical trials, department of corrections) – No limits on physician dispensing of other medications •  Requires counterfeit-proof prescription pads (effective August 29, 2011) •  Register as controlled substance prescribing physicians (effective January 1, 2012) HB  7095  (Florida  Pill  Mill  Bill)   44© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 44
  • 45. •  Early impact of reform on prescribing and dispensing practices •  Only injuries that occurred after the law change were included in treatment group Scope  Of  The  Study   45© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 45
  • 46. •  Pre-post policy implementation –  Treatment group: new injuries arising between July-September, 2011 (Ban effective 7/1/11) –  Comparison group: new injuries arising between July-September, 2010 –  Both groups had Rx filled through December of the year of injury (3-6 months of experience) •  Data: –  25% of Florida claims –  Indemnity and medical-only claims –  Case-mix adjusted Methods  And  Data   46© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 46
  • 47. Pre-­‐  And  Post-­‐Reform  Claim   Characteris:cs  Were  Similar   47© Copyright 2014 WCRI. All Rights Reserved. Pre-­‐Reform   Post-­‐Reform   Number  Of  Claims   11,867   10,623   Average  Age   41   41   %  Female   42%   40%   %  Indemnity  Claims   24%   22%   Average  Medical  Payments   $2,464   $2,521   Average  #  Physician  Visits   3   3   © Copyright 2014 WCRI. All Rights Reserved. 47 Source: Impact of Banning Physician Dispensing of Opioids in Florida (Thumula, 2013)
  • 48. Physician  Dispensing  And  Use  Of  Pain   Medica:ons  Unchanged   48© Copyright 2014 WCRI. All Rights Reserved. Pre-­‐Reform   Post-­‐Reform   Number  of  Rxs   22,255   19,017   %  Physician-­‐Dispensed  Rxs   52%   52%   %  All  Pain  Medica:ons   61%   61%   © Copyright 2014 WCRI. All Rights Reserved. 48
  • 49. High  Physician  Compliance  With  Reform   In  First  3-­‐6  Months  Of  Cases   49© Copyright 2014 WCRI. All Rights Reserved. 0.0% 0.5% 1.0% 1.5% 2.0% 2.5% 3.0% 3.5% 4.0% Pre-Reform Post-Reform ProportionOfClaimsWithRx Physician-­‐Dispensed  Schedule  II,  III  Opioids   © Copyright 2014 WCRI. All Rights Reserved. 49
  • 50. •  Of those with physician-dispensed stronger opioids after the ban: – 69% surgical cases – 21% out-of-state providers Why  Didn’t  Physician-­‐Dispensed     Schedule  II,  III  Opioids  Drop  To  Zero?   50© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 50
  • 51. Physician  Dispensing  Of  Stronger  Opioids   Fell  AYer  The  Ban   3.5% 0.5% Pre-Reform Post-Reform ProportionOfClaimsWithRx 51© Copyright 2014 WCRI. All Rights Reserved. Physician-­‐ Dispensed   Opioids  (II,  III)   © Copyright 2014 WCRI. All Rights Reserved. 51
  • 52. No  Change  In  Pharmacy  Dispensing  Of   Schedule  II,  III  Opioids   12.0% 12.1% 3.5% 0.5% Pre-Reform Post-Reform ProportionOfClaimsWithRx 52© Copyright 2014 WCRI. All Rights Reserved. Physician-­‐ Dispensed   Opioids  (II,  III)   Pharmacy-­‐ Dispensed   Opioids  (II,  III)   © Copyright 2014 WCRI. All Rights Reserved. 52
  • 53. Physician  Dispensing  Of  NSAIDs  And  Weaker   Opioids  Increased  Post-­‐Reform   9.0% 9.8% 23.8% 26.0% 3.5% 0.5% Pre-Reform Post-Reform ProportionOfClaimsWithRx 53© Copyright 2014 WCRI. All Rights Reserved. Physician-­‐ Dispensed   Opioids  (II,  III)   Physician-­‐ Dispensed   Weaker  Opioids   Physician-­‐ Dispensed  NSAIDs   © Copyright 2014 WCRI. All Rights Reserved. 53
  • 54. Recap:  Did  The  Florida  Ban  Reduce  The  Overall   Use  Of  Opioids  By  Injured  Workers?     •  High levels of physician compliance with the ban •  Fewer workers received stronger opioids 54© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 54
  • 55. Ques:on  Raised:    Does  Physician   Dispensing  Lead  To  More  Opioids?   •  Physician-­‐dispensers  switched  to  other  pain   medica:ons  in  the  wake  of  the  ban   — No  change  in  pharmacy-­‐dispensed  schedule  II,  III   opioids   — Increase  in  percentage  of  claims  with  physician-­‐ dispensed  NSAIDs  and  weaker  opioids   •  This  raises  ques:ons  if  physicians  dispensed   unnecessary  opioids  pre-­‐ban     •  Upcoming  study  will  examine  longer-­‐term   impact  of  the  ban   55© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 55
  • 56. •  To purchase the study, Impact of Banning Physician Dispensing of Opioids in Florida, go to: •  WWW.WCRINET.ORG •  For comments/questions about the findings: WCRI@WCRINET.ORG Follow WCRI on social media: For  More  Informa:on   56© Copyright 2014 WCRI. All Rights Reserved.© Copyright 2014 WCRI. All Rights Reserved. 56